LIB-01

About Dicot

Dicot Pharma is a clinical-stage biotech company targeting the large and underserved market for male sexual health disorders, specifically erectile dysfunction and premature ejaculation. Its lead candidate, LIB-01, has completed a Phase 2a study showing a potential duration of action of at least 7 days, positioning it as a potential next-generation potency drug. The company is leveraging a novel mechanism of action involving the melanocortin system to differentiate from existing PDE5 inhibitors. With clinical studies underway and recognition from analysts like Oppenheimer, Dicot is advancing towards later-stage development in a multi-billion dollar market.

Therapeutic Areas